J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522204-24-00

Enrollment

Registered

2026-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

Brief summary

Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV CR defined as no vomiting and no rescue medication

Interventions

DRUGONDANSETRON

DRUGAPREPITANT

DRUGPALONOSETRON

DRUGCOMBINATIONS

DRUGLagipra

DRUGGRANISETRON

DRUGDEXAMETHASONE

DRUG0.9% sodium chloride

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV CR defined as no vomiting and no rescue medication	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 24, 2026